UCBJY - UCB SA

Other OTC - Other OTC Delayed price. Currency in USD
40.14
0.00 (0.00%)
At close: 3:47PM EDT
Stock chart is not supported by your current browser
Previous close40.14
Open0.00
Bid0.00 x 0
Ask0.00 x 0
Day's range0.00 - 0.00
52-week range
Volume36
Avg. volume69
Market cap15.166B
Beta0.64
PE ratio (TTM)16.34
EPS (TTM)2.46
Earnings dateN/A
Forward dividend & yield0.63 (1.52%)
Ex-dividend date2017-04-28
1y target estN/A
Trade prices are not sourced from all markets
  • PR Newswire7 days ago

    UCB to Expand Epilepsy Portfolio With Strategic Acquisition of Midazolam Nasal Spray From Proximagen

    Midazolam Nasal Spray (USL261), is a nasally administered investigational midazolam formulation intended as a rescue treatment of acute repetitive seizures (ARS) in patients with epilepsy, which has completed Phase 3 clinical development and is ready to be filed as a New Drug Application (NDA) in the course of 2018. Nasal administration could provide significant value to patients who currently have limited treatment options.

  • PR Newswire22 days ago

    UCB Strengthens Research Capabilities With Acquisition of Element Genomics, a Duke University Biotech Spin-off

    UCB announces the acquisition of Element Genomics, a small-size biotech spin-off from Duke University, based in Durham, North Carolina (USA). At the core of the Element Genomics platform is a suite of technologies to improve understanding of genome structure and function such as CRISPR editing technologies used for genomic and epigenomic regulatory region analysis and modulation, underpinned and enabled with advanced informatics capabilities, and driven by a strong scientific team. Element Genomics' proven technologies and expertise will enhance UCB's scientific research platform enabling the company to continue to enrich its pipeline, in particular strengthening target discovery and characterization in disease relevant systems.

  • Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session
    Zacks7 months ago

    Regulus Therapeutics (RGLS) Looks Good: Stock Adds 5.6% in Session

    Regulus Therapeutics Inc. (RGLS) was a big mover last session, as the company saw its shares rise nearly 6% on the day amid huge volumes

By using Yahoo you agree that Yahoo and partners may use Cookies for personalisation and other purposes